Brexpiprazole: A New Treatment Option for Schizophrenia and Major Depressive Disorder

Annals of Pharmacotherapy

Volumn 51, Issue 4, 2017, Pages 315-322

  Markovic, Marija ^a   Gallipani, Alyssa ^b   Patel, Krina H ^a,c   Maroney, Megan ^a,c  

^a RUTGERS UNIVERSITY   (United States)

^b BROOKLYN HOSPITAL CENTER   (United States)

^c MONMOUTH MEDICAL CENTER   (United States)

Author keywords

antipsychotic; brexpiprazole; major depressive disorder; schizophrenia

Indexed keywords

BREXPIPRAZOLE; CYTOCHROME P450 2D6 INHIBITOR; OXIDOREDUCTASE INHIBITOR; SEROTONIN 1A RECEPTOR; ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR; DRD2 PROTEIN, HUMAN; NEUROLEPTIC AGENT; QUINOLONE DERIVATIVE; THIOPHENE DERIVATIVE;

AKATHISIA; ANXIETY DISORDER; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG COST; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; DRUG TOLERABILITY; DYSPEPSIA; FATIGUE; HEADACHE; HUMAN; INCREASED APPETITE; MAJOR DEPRESSION; PARTIAL AGONISM; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; RESTLESSNESS; REVIEW; RHINOPHARYNGITIS; SCHIZOPHRENIA; SOMNOLENCE; TREMOR; AGONISTS; COMBINATION DRUG THERAPY; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; METABOLISM; WEIGHT GAIN;

ANTIDEPRESSIVE AGENTS; ANTIPSYCHOTIC AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DEPRESSIVE DISORDER, MAJOR; DRUG THERAPY, COMBINATION; HUMANS; QUINOLONES; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTORS, DOPAMINE D2; SCHIZOPHRENIA; THIOPHENES; WEIGHT GAIN;

EID: 85014709922     PISSN: 10600280     EISSN: 15426270     Source Type: Journal    
DOI: 10.1177/1060028016678262     Document Type: Review

References (23)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
2. Lehman AF, Lieberman JA, Dixon LB. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatry. 2004;161(2, suppl):1-56.
3. Rush AJ, Kraemer HC, Sackheim HA. Report by the ACNP task force on response and remission in major depressive disorder. Neuropsychopharmacology. 2006;31:1841-1853.
4. Gelenberg AJ, Freeman MP, Markowitz JC. Practice guideline for the treatment of patients with major depressive disorder, third edition. Am J Psychiatry. 2010;167(suppl):1-152.
5. Rexulti (brexpiprazole) [product information]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2015.
6. Oosterhof CA, El Mansari M, Blier P., Acute effects of brexpiprazole on serotonin, dopamine, and norepinephrine systems: an in vivo electrophysiologic characterization. J Pharmacol Exp Ther. 2014;351:585-595.
7. Maeda K, Sugino H, Akazawa H. Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther. 2014;350:589-604.
8. 1A receptors. Pharmacol Biochem Behav. 2014;124C:245-249.
9. Citrome L, Stensbol TB, Maeda K., The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders? Exp Rev Neurother. 2015;15:1219-1229.
10. Correll CR, Skuban A, Ouyang J. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double-blind, placebo-controlled trial. Am J Psychiatry. 2015;172:870-880.
11. Kane JM, Skuban A, Ouyang J. A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia. Schizophr Res. 2015;164:127-135.
12. Thase ME, Youakim JM, Skuban A. Efficacy and safety of adjunctive brexpiprazole 2 mg in major depressive disorder: a phase 3, randomized, placebo-controlled study in patients with inadequate response to antidepressants. J Clin Psychiatry. 2015;76:1224-1231.
13. Thase ME, Youakim JM, Skuban A. Adjunctive brexpiprazole 1 and 3 mg for patients with major depressive disorder following inadequate response to antidepressants: a phase 3, randomized, double-blind study. J Clin Psychiatry. 2015;76:1232-1240.
14. Duru G, Fantino B., The clinical relevance of changes in the Montgomery-Asberg Depression Rating Scale using the minimum clinically important difference approach. Curr Med Res Opin. 2008;24:1329-1335.
15. Nelson C, Skuban A, Zhang P. Long-term safety of adjunctive brexpiprazole in MDD: results from two 52-week open label studies. Poster presented at: 168th American Psychiatric Association Annual Meeting; May 16-20, 2015; Toronto, Canada.
16. Correll CU, Skuban AS, Ouyang J. Long-term safety of brexpiprazole (OPC-34712) in schizophrenia: results from two 52-week open-label studies. Poster presented at: 15th International Congress on Schizophrenia Research (ICOSR); March 28 to April 1, 2015; Colorado Springs, CO.
17. Abilify (aripiprazole) [product information]. Tokyo, Japan: Otsuka Pharmaceutical Co, Ltd; 2014.
18. Vraylar (cariprazine) [product information]. Parsippany, NJ: Actavis, Inc; 2015.
19. Latuda (lurasidone) [product information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; 2013.
20. Seroquel XR (quetiapine fumarate) [product information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2009.
21. Red Book Online System. Greenwood Village, CO: Thomson Reuters (Healthcare), Inc. http://micromedex.com/products/product-suites/clinical-knowledge/redbook.
22. Sussman M, Yu K, Kamat SA. Cost-effectiveness of brexpiprazole adjunctive treatment for major depressive disorder. J Affect Disord. 2017;207:54-62. doi:http://dx.doi.org/10.1016/j.jad.2016.09.006.
23. Leucht S, Cipriani A, Spinelli L. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple treatments meta-analysis. Lancet. 2013;382:951-962.